Search the Newsreel

Sanofi Discontinues Development of OX40L Inhibitor Amlitelimab in Atopic Dermatitis

Sanofi has discontinued the clinical development of amlitelimab for moderate to severe atopic dermatitis (AD), citing insufficient efficacy and safety data to significantly improve upon current standard-of-care treatments. Despite long-term data from the ESTUARY study showing durable maintenance of clinical response, Sanofi concluded that …

Sanofi ends amLitelimab program in atopic dermatitis amid portfolio review

Sanofi has discontinued the development of its anti‑OX40L monoclonal antibody, amLitelimab, for moderate to severe atopic dermatitis, concluding that its efficacy and safety data do not warrant regulatory submissions or significant improvement over existing treatments. This decision is part of a broader strategic portfolio …

Scribe Therapeutics Sets IPO Of 8.58 Mln Shares At $15/Shr; Enters Private Placement With Sanofi

(RTTNews) - Scribe Therapeutics Inc. (SCTX), a clinical-stage biotechnology company, announced pricing of its upsized initial public offering of 8.58 million shares of its common stock at the high end of the range at a public offering price of $15 per share. In addition …

Popular insulin product enters shortage as other pens leave market

Sanofi's Lantus Solostar pen, a popular long-acting insulin product, is experiencing supply issues due to increased demand and broader market dynamics, prompting users to struggle with finding the medication. While not officially designated an FDA shortage, the company anticipates the situation will improve in …

Sanofi’s New CEO Has A Simple To-Do List: Deals Or Buybacks

Berenberg, an investment bank, suggests Sanofi's CEO Belén Garijo needs to either pursue acquisitions to drive growth and close a "deep" valuation gap or implement a EUR5 billion share buyback program that could boost earnings per share by about 5%. The bank emphasizes the …

Sanofi (SNY) to Post Quarterly Earnings on Thursday

Sanofi Elevates Top US Atty To General Counsel

French pharmaceutical company Sanofi SA announced the promotion of its North American general counsel to group general counsel. This change follows the departure of the current legal chief after four years in the role. The article, however, does not provide the name of the …

FDA issues untitled letters to Sanofi and Viatris for false advertising

The FDA's Office of Prescription Drug Promotion has sent untitled letters to Sanofi and Viatris for making misleading claims in their product promotions. Sanofi was cited for an email promoting Beyfortus, which incorrectly suggested it prevents general RSV, while Viatris was reprimanded for a …

How AI is Reshaping the Patient Care Journey

Sanofi is leveraging Digital and AI technologies to transform the patient care journey, addressing fragmentation from diagnosis to long-term treatment. Their approach spans pre-prescription (identification and diagnosis) and post-prescription (onboarding and support) phases. By integrating AI-driven tools like AccelRare, FabryFind, iCare+, and Companion App, …

FDA calls out Sanofi emails for giving 'misleading impression' of Beyfortus use in RSV

The FDA has issued an untitled letter to Sanofi regarding its promotional emails for the RSV antibody Beyfortus. The agency claims Sanofi's emails create a "misleading impression" by presenting Beyfortus as a general RSV preventative, rather than specifically for lower respiratory tract disease as …

Amundi group (SNY) reports 68.7M-share, 5.65% beneficial ownership position in Sanofi

Amundi and its subsidiary Amundi Asset Management have disclosed a beneficial ownership of 68,651,904 Sanofi common shares, representing 5.65% of the class. They report shared voting power over 36,655,093 shares and shared dispositive power over all 68,651,904 shares. A significant portion of these shares …

Cincinnati startup Enable Injections scores significant FDA win

Cincinnati-based startup Enable Injections, in collaboration with Sanofi, received FDA approval for its CirCliq device. This approval marks a significant milestone for the company, which continues to expand its hiring in the region. The firm is recognized as a local unicorn within the biotech …

Sanofi continues tweaks to executive roster as new CEO Garijo settles in

Sanofi is continuing to adjust its executive team under new CEO Belén Garijo, with several notable changes including expanding the role of vaccine chief Thomas Triomphe to include China, and Madeleine Roach becoming president for Germany, Switzerland, and Austria. The company also announced the …

Press Release: Sanofi evolves its Executive Committee to support its next strategic chapter

Sanofi has announced significant changes to its Executive Committee, effective September 1, 2026, to streamline leadership across its businesses, R&D, and global functions. These changes are intended to support the company's strategic priorities and prepare for its next growth chapter. Key appointments include new …

Lobbying Update: $920,000 of SANOFI US SERVICES INC lobbying was just disclosed

SANOFI US SERVICES INC (SNY) disclosed $920,000 in lobbying expenditures for Q2 2026, covering a wide range of issues including drug pricing, FDA regulations, and vaccine-related matters. Concurrently, an analysis of hedge fund activity shows significant changes in SNY stock holdings, with some institutions …

SANOFI : Gets a Neutral rating from JP Morgan

JP Morgan has reaffirmed its "Neutral" rating for Sanofi, maintaining an unchanged target price of EUR 95. This news comes amidst a broader context of European equities trading lower in the US and various other announcements related to Sanofi's drug approvals and research collaborations.

Sanofi survey uncovers Type 1 diabetes misconceptions and screening gaps

A new survey commissioned by Sanofi reveals widespread misconceptions about Type 1 diabetes and significant gaps in screening. Many adults are unaware that Type 1 diabetes can manifest in adulthood and are hesitant to get screened despite identifying as at risk. The findings suggest …

Devika Gupta Joins Sanofi as Head of Value for Healthcare Systems & Economics

Sanofi has appointed Devika Gupta as Head of Value for Healthcare Systems & Economics to bolster its market access, pricing, and value-based healthcare strategies globally. Gupta brings over 25 years of experience from previous leadership roles at Merck, Pfizer, Campbell Alliance, Johnson & Johnson …

Sanofi's Oral TREM2 Agonist SAR448851 Advances to Phase 2 TREMHANCE Trial in Early Alzheimer Disease

Sanofi's oral TREM2 agonist, SAR448851, is progressing to a Phase 2 clinical trial named TREMHANCE for early Alzheimer's disease. The trial will evaluate the drug's efficacy and safety, with the primary endpoint being the change in plasma p-tau217 at week 48, aiming to shift …

Aqemia Expands Sanofi AI Drug Discovery Deal

Aqemia and Sanofi have expanded their multi-year drug discovery collaboration, with Aqemia announcing a new therapeutic target nomination. This expansion makes Aqemia eligible for up to $140 million in aggregate payments. The partnership utilizes Aqemia's physics-based generative AI platform, Qemi, to design molecules for …

Aqemia and Sanofi Expand Their Research Collaboration

Aqemia and Sanofi have expanded their multi-year research collaboration, initially announced in December 2023. The expansion involves the nomination of a new therapeutic target and an additional milestone payment to Aqemia, bringing the potential total payments to $140 million. This partnership leverages Aqemia's generative …

FDA clears Sarclisa Escena on-body injector for Sanofi (NASDAQ: SNY)

The US FDA has approved Sanofi's subcutaneous Sarclisa Escena (isatuximab-irfc) for multiple myeloma, making it the first anticancer treatment to be administered via an on-body injector or manual subcutaneous injection. This approval expands Sarclisa's use across all existing IV indications. The pivotal IRAKLIA phase …

Sanofi Doesn’t Want AI to Automate Work. It Wants to Reinvent It.

Sanofi is aiming to become the first biopharma company powered by AI at scale, applying AI throughout the entire medicine development journey from discovery to commercialization. Emmanuel Frenehard, Sanofi's Chief Digital Officer, emphasizes that AI should be used to reinvent business processes rather than …

Sanofi joins the mRNA vaccine patent wars

Sanofi has initiated lawsuits against Pfizer and Moderna, alleging infringement of its patents related to the delivery of messenger RNA using lipid nanoparticles in their COVID-19 and RSV vaccines. Acquired through the 2021 Translate Bio purchase, these patents represent Sanofi's strategy to gain value …

Sanofi, Lilly back AdvanCell's $315M radiopharmaceutical push

The article reports that Sanofi and Lilly are investing in AdvanCell's $315 million radiopharmaceutical initiative. This significant backing from major pharmaceutical companies highlights growing interest and investment in radiopharmaceutical development. The collaboration aims to advance AdvanCell's efforts in this specialized area of medicine.

Sanofi opens new chapters in Pfizer, Moderna mRNA patent litigation sagas

Sanofi has initiated new patent infringement lawsuits against Pfizer and Moderna, targeting the lipid nanoparticle (LNP) technology used in their COVID-19 vaccines and Moderna's RSV vaccine. Sanofi claims the LNP tech, developed by its acquired Translate Bio, infringes on its patents related to mRNA …

Why Is Sanofi Consumer Healthcare India Share Price Falling Key Reasons 2026

Can Sanofi Rely on Dupixent to Drive Long-Term Revenue Growth?

Sanofi-ADR (NASDAQ:SNY): A High-Yield Dividend Stock with Strong Fundamentals

Is It Worth Considering Sanofi Consumer Healthcare India Limited (NSE:SANOFICONR) For Its Upcoming Dividend?

Strong Buy Rating on Sanofi (SNY) Following Positive Study Resul

SANOFI-ADR (NASDAQ:SNY): A Quality Dividend Stock with a 5.31% Yield and Strong Fundamentals

Why Is Sanofi India Share Price Falling Key Reasons 2026

Sanofi Consumer Healthcare India Reports Strong Q1'26 Performance with 33% Revenue Growth

Sanofi India Publishes Q4 FY26 Financial Results in Compliance with SEBI Regulations

Sanofi India Q1 net profit down 14% as revenue declines amid partnership transition